Sanofi S.A. (SNY – Q2FY20) – Strong growth from Dupixent making growth positive.

in , on September 7, 2020

Sanofi’s country launch program has 89 planned launches in FY20 which are on track. Its U.S. launch in pediatric atopic dermatitis is off to a strong start with already over 500 unique prescribers for Dupixent. It achieved an important regulatory milestone in the quarter, both for Sanofi China strategy and for the Dupixent franchise with the approval in adult AD in China.

Executive Summary

Financial Statements

– Income Statement and Forecast
– Balance Sheet
– Cash Flow
– Q2FY20 Results – Overview
– 1HFY20 Results – Overview
– Q2FY20 & 1HFY20 – Geographic Revenue
– Q2FY20 & 1HFY20- Segment Performance
– Q2FY20 – R&D Update
– Guidance
– Conclusion

Historical Performance

– Key Ratios
– Profitability Ratios, Asset Turnover Ratio, Growth Ratio
– Per Share Items and Key Ratios
– Key Balance Sheet and Cash Flow Items
– P/E band

Product Performance and Key Developments

– Ownership
– Competition
– Key Developments

Valuation and Consensus Performance

– Analyst Recommendations

Market Price Performance

CrispIdea Coverage

No of Pages : 73

Release Information

  • Released
    :

    September 7, 2020

  • Last Updated
    :

    September 7, 2020